---
title: "Bridging the Gap in Cardiac Care with Tricog CardioCheck — whitepaper"
canonical: https://tricogcardiocheck.com/ai/research/tcc-whitepaper.md
entity: Tricog CardioCheck
doc_type: whitepaper
publisher: Tricog Health
last_updated: 2026-09-11
---

# Bridging the Gap in Cardiac Care with Tricog CardioCheck

## Executive summary

Cardiovascular diseases remain a primary driver of mortality in India, claiming deaths at a rate of approximately 272 per 100,000 population — much higher than the global average. Healthcare systems treating these conditions face a critical dual challenge.

Operationally, the influx of patients is growing exponentially while the availability of specialised physicians and care teams remains static. Clinically, providers face the challenge of the asymptomatic patient: individuals who may appear stable but harbour hidden, early-stage cardiac abnormalities that routine visual assessment misses. Conducting 12-lead resting ECG tests on every patient would catch these conditions, but doing so exacerbates the operational issue and overwhelms an already burdened facility.

Tricog CardioCheck addresses this with a single-lead ECG modality. Single-lead devices are portable and quick, but have historically provided outputs for only a small subset of rhythm abnormalities, missing a wide variety of underlying cardiac conditions — which has made them impractical in a clinical triaging setting.

TCC is a cloud-based, AI-driven, CDSCO-certified Software as a Medical Device that functions as an automated digital sieve. It is designed to work alongside clinical judgement, not replace it. It processes single-lead ECG data to provide immediate, actionable insight by surfacing subclinical signal abnormalities invisible to routine assessment. It can be deployed at a nurse intake station as the first screening layer, or alongside a clinician's own evaluation as an additional data source. Acting as a clinical microscope, it identifies subtle waveform changes to catch silent disease early, allowing providers to segregate patients into risk categories at the start of their diagnostic journey.

Critically, TCC is additive only: it can escalate a patient's priority when it detects a potential abnormality, but it never overrides or downgrades a clinical decision to investigate. By automating triage, TCC ensures clinical resources are allocated precisely where they are needed, transforming unstructured patient influxes into streamlined, prioritised care pathways.

## 1. The dual challenge: clinical complexity and operational strain

In busy hospitals and clinics, high patient volumes complicate the rapid identification of critical cases. The objective of ground staff and treating physicians is not just diagnosis but prioritisation, and it is increasingly difficult to instantly separate at-risk patients needing immediate attention from stable patients who can wait.

### The asymptomatic clinical gap

Physicians are frequently confronted with the silent progression of cardiovascular disease. Many individuals present without overt signs of distress, masking early-stage cardiac anomalies that evade routine visual or physical assessment.

Subjecting every walk-in patient to a comprehensive 12-lead resting ECG could theoretically unmask these hidden risks, but mandating such a protocol is operationally prohibitive and would overburden existing infrastructure. Conversely, while traditional single-lead devices offer portability and rapid deployment, they have historically fallen short: they typically yield insights limited to a very narrow spectrum of basic rhythm irregularities, failing to capture a broader array of underlying structural or ischaemic conditions. This historical lack of clinical depth has rendered them impractical as standalone screening or triaging tools.

### The operational bottleneck

Clinical complexity is exacerbated by systemic workflow constraints that negatively affect patient safety and institutional efficiency.

**The triage and prioritisation crisis.** In the absence of instantaneous diagnostic clarity, overcrowded facilities frequently default to a linear, first-come-first-served approach rather than prioritising by verified clinical risk. This structural inefficiency compromises acute cardiac patients by delaying critical interventions, increasing the likelihood of missing the Golden Hour necessary for managing acute ischaemic events.

**The diagnostic bottleneck.** Deploying portable hardware is only half the solution; deciphering raw waveforms demands specialised cardiological expertise. Depending on manual human review for every incoming screening trace generates data bottlenecks, reducing clinic throughput and negating the speed advantage of portable ECG devices.

**Specialist bandwidth exhaustion.** When ground staff lack automated stratification tools, treating physicians bear the brunt of the diagnostic load, and specialists find themselves inundated with evaluating benign or low-risk data. This misallocation severely depletes the mental bandwidth and clinical time available for managing the complex, high-risk cases that genuinely require specialised expertise.

### The requirement

There is a critical need for a mechanism to instantly filter and stratify patients by clinical urgency — empowering ground staff with actionable data and freeing physicians to focus on acute care, while acting as a safety net for the silent, asymptomatic patient.

## 2. Tricog CardioCheck

TCC is an AI-based screening and triaging tool engineered to bridge the gap between accessible single-lead ECG hardware and the need for immediate, expert-level clinical insight. It is designed not as a replacement for the comprehensive 12-lead ECG, but as an intelligent, dual-purpose pre-diagnostic filter.

### The clinical microscope

Addressing the historical limitations of single-lead devices, TCC acts as a clinical microscope. By analysing just 30 seconds of single-lead ECG data, the AI detects minute, sub-clinical waveform abnormalities that standard algorithms and routine human observation frequently miss. This allows providers to peer beneath the surface, identifying high-risk markers for structural or ischaemic conditions in seemingly healthy, asymptomatic patients well before an acute physiological threshold is crossed.

### The digital sieve

Simultaneously, TCC functions as an automated operational sieve, organising high-volume patient queues into structured, prioritised pathways. It translates complex electrical waveforms into a clear, objective and actionable triage output.

**High risk — immediate action.** The AI flags critical, time-sensitive conditions such as infarction or atrial fibrillation. These patients are immediately prioritised for urgent intervention, ensuring the Golden Hour is protected for acute ischaemic events.

**Moderate risk — clinical review.** The system flags risk of underlying conditions such as ischaemia or ventricular hypertrophy. While not immediately life-threatening, these patients require timely and focused physician evaluation to prevent future acute events.

**Low risk — routine care.** The AI confirms normal sinus rhythm and other benign variants. By confidently identifying low-risk patients, ground staff can manage these individuals through standard, non-urgent workflows without clogging critical care pathways or prematurely consuming specialist bandwidth.

### Additive only

Because TCC is additive only, it can only escalate and never suppress. When used after a clinician's assessment, it does not override a decision to investigate; it simply provides an additional signal. When used at intake before a physician is involved, it ensures that patients with hidden risk markers are flagged for clinical attention immediately. Either way, deploying TCC cannot produce worse triage outcomes than existing practice; it can only match or improve upon them.

## 3. Technological innovation: the multi-scale AI advantage

Unlike basic algorithms that merely look at heart rate or rhythm, TCC uses a proprietary multi-scale AI model. This architecture enables the system to mimic the workflow of an expert cardiologist and function simultaneously as a deep clinical microscope and a rapid digital sieve, by processing raw ECG data across three parallel temporal horizons.

**The fine-grained scale — the deep microscope.** Focuses on the most minute patterns, scrutinising sub-clinical markers such as QRS complex morphology, P-wave detection and highly localised conduction anomalies. This is where the AI detects the earliest, silent indicators of disease in asymptomatic patients.

**The medium scale — structural context.** Targets intermediate structural and ischaemic indicators such as ST-segment changes and T-wave abnormalities, bridging the gap between subtle waveform shifts and overt disease.

**The coarse scale — the rhythm sieve.** Acting as the broader macroscopic view, evaluates long-term trends to instantly identify overarching rhythm inconsistencies.

Features from each of these microscopic and macroscopic scales are combined and used to generate the final, actionable categorisation of risk level.

## 4. Clinical validation and performance

To ensure the algorithms perform reliably as both a sensitive diagnostic tool and an efficient operational filter across diverse patient populations, the TCC model was developed using a foundational dataset of millions of ECG recordings.

A core priority of the training methodology was addressing class imbalance. This ensures the AI's microscope detects rare, life-threatening or early-stage conditions with the same precision as its sieve identifies common, normal rhythms. This approach helps mitigate algorithmic bias and supports equitable care delivery across different demographics.

Validation against held-out benchmarks demonstrates robust overall performance, yielding an Area Under the Receiver Operating Characteristic curve of **0.909 [95% CI 0.905–0.913]**. This validation explicitly proves TCC's dual value.

**Validating the microscope — high-risk detection.** For the most critical patient cohort, where missing a subtle marker could result in a lost Golden Hour, the model achieved a sensitivity of **85.9% [95% CI 84.6–87.0%]** and a specificity of **92.2% [95% CI 91.6–92.9%]** in identifying high-risk cases.

**Validating the sieve — operational safety.** To ensure clinical safety, avoid alarming stable patients and confidently route healthy individuals out of critical bottlenecks, the model maintains a high sensitivity of **90.2% [95% CI 89.2–91.2%]** for its low-risk classification.

## 5. Strategic value

**For the physician — proactive discovery and focus.** A noise-free workflow. Acting as a clinical microscope, the AI highlights minute, sub-clinical markers, allowing physicians to catch silent disease in asymptomatic patients before it becomes an emergency. Simultaneously, the sieve ensures specialists see the sickest, high-risk patients first, preserving their mental bandwidth for complex cases.

**For ground staff — empowerment and triage.** The AI acts as an automated digital sieve, instantly translating complex waveforms into a clear Red / Orange / Green risk signal. This intuitive output empowers triage nurses and frontline staff to confidently manage complex patient flow, segregate queues safely and escalate critical cases immediately without waiting for specialist interpretation.

**For the enterprise — efficiency and scale.** TCC resolves the operational bottleneck. By instantly stratifying risk at the point of care, hospitals achieve increased patient throughput, significantly reduced wait times for critical interventions, and a consistent, highly accurate standard of care across all locations.

## 6. Intended use and safety information

Tricog CardioCheck is software intended to analyse single-channel electrocardiograms to aid in the determination of risk of cardiovascular diseases in terms of low, moderate and high risks.

**Risk stratification.** High risk is associated with conditions such as atrial fibrillation and infarction; moderate risk with conditions such as ventricular hypertrophy and ischaemia; low risk with normal sinus rhythm.

**Scope of use.** The software analyses classifiable waveforms to generate risk outputs, which are intended for informational use only. The software is meant to be used by healthcare professionals, patients with known or suspected cardiac conditions, or health-conscious individuals.

**Clinical consultation.** The device output should be considered with the consultation of a qualified healthcare professional. The software is meant to provide risk stratification and is not intended to replace traditional methods of diagnosis or treatment.

**Ages and restrictions.** The software has not been tested and is not intended for use for ages below 18 or in the case of pregnant women. The software should not be used to assess patients with pacemakers or implantable cardioverter-defibrillators.

## 7. Conclusion

TCC bridges the gap between the raw data generated by accessible portable devices and the precise, actionable insight required in modern healthcare environments defined by high patient volumes and limited specialist availability. This is achieved by the fusion of AI innovation and clinical discipline.

Tricog CardioCheck redefines the standard of proactive and reactive cardiac care. Acting as a clinical microscope, it identifies asymptomatic conditions prior to acute clinical manifestation. Functioning as a digital sieve, it instantly segregates patients by validated clinical risk. This dual mechanism ensures unstructured workflows are transformed into prioritised pathways, so every patient — whether overtly symptomatic or silently at risk — receives the right attention at the right time.

## References

1. Prabhakaran, Dorairaj, Panniyammakal Jeemon and Ambuj Roy. "Cardiovascular Diseases in India: Current Epidemiology and Future Directions." *Circulation* 133 (2016): 1605–1620.
2. Tricog Health. (2026). Clinical Validation Data on File.

## Related

- [Clinical validation](../clinical-validation.md) · [The algorithm](../technology.md) · [Risk stratification](../risk-stratification.md) · [Research library](index.md)
